Brief: Inova Schar Cancer Adopts Immunovia’S Pancreasure Test For Its High-Risk Surveillance Program
15/09/2025 07:06
Sept 15 (Reuters) - Immunovia AB (publ) IMMNOV.ST: INOVA SCHAR CANCER ADOPTS IMMUNOVIA’S PANCREASURE TEST FOR ITS HIGH-RISK SURVEILLANCE PROGRAM Source text: ID:nMFNbHvqgS Further company coverage: IMMNOV.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Immunovia AB (publ)
See all newsBrief: Immunovia Publishes Data On Pancreasure In Hereditary, Familial High-Risk Individuals
Brief: Immunovia To Carry Out Rights Issue Of About SEK 63 Million
Sweden's Immunovia Q2 sales rise on PancreaSure test uptake
Brief: Immunovia Reports Q2 Operating Loss Of SEK 22.8 Million
Brief: PancreaSure Achieves 88% Sensitivity In Immunovia Study